Home » Topics » Regulatory » EMA

EMA
RSS

Refixia recommended for approval in E.U.

March 27, 2017

EMA validates regulatory filing of tildrakizumab in Europe

March 27, 2017

Opdivo approved in Japan for head and neck cancer, recommended for approval in E.U.

March 27, 2017

EMA committee recommends approval of Trumenba

March 27, 2017

EMA accepts Shionogi's MAA submission for naldemedine

March 27, 2017

EMA committee recommends approval of Keytruda for classical Hodgkin's lymphoma

March 27, 2017

EMA committee recommends approval of Axumin for use in prostate cancer

March 27, 2017

EMA grants orphan drug designation to NiCord in HSCT

March 24, 2017

EMA accepts for review brexpiprazole MAA for schizophrenia in adults

March 24, 2017

EMA gives positive scientific advice on approval pathway for Actinium's Iomab-B

March 22, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...